Inside Moderna’s Biggest mRNA Test Since COVID

The gist

1. Each patient's tumor DNA is sequenced, 34 key mutations are selected by algorithm, and a bespoke vaccine is manufactured in about 42 days.
2. Phase 2 melanoma data showed 80% disease-free survival at 5 years, with the vaccine paired with Keytruda in those cases.
3. The current mutation-selection algorithm has not changed since Phase 1, and Bancel says analyzing non-responders from Phase 3 is the next step to improving it.
4. Moderna is expanding the approach beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, and possibly autoimmune disorders.